FrancophonIA/ELRC3.0 huggingface dataset:
English: In a main study involving medical records from 115 men, PET scans with Axumin correctly detected cancers in 99% of all patients whose cancer had in fact returned (as confirmed by tissue sampling).
Estonian: Põhiuuringus, milles analüüsiti 115 mehe terviseandmeid, olid Axuminiga tehtud PET-uuringute tulemused, mis näitasid vähi taasteket, õiged 79% juhtudest; seda kinnitasid hilisemad laboratoorsed koeuuringud.
English: How does Axumin work?
Estonian: Kuidas Axumin toimib?
English: All men enrolled in this study had already shown some signs that the cancer might have returned, such as increases in blood levels of PSA, a protein produced in the prostate glands.
Estonian: Kõigil uuringus osalenud meestel olid ilmnenud vähi võimaliku taastekke nähud, näiteks PSA (eesnäärmes tekkiv teatud valk) sisalduse suurenemine veres.
English: Axumin is a diagnostic medicine used with a body scan to check whether or not prostate cancer has returned.
Estonian: Axumin on diagnostikaravim, mida kasutatakse kontrollimisel, kas patsiendi eesnäärmevähk on taastunud.
English: It is used specifically with the body scan known as positron-emission tomography (PET) in men whose blood test for prostate-specific antigen (PSA) indicate that the cancer may have returned.
Estonian: Täpsemalt kasutatakse seda positronemissioontomograafia (PET) uuringul meestel, kelle prostataspetsiifilise antigeeni (PSA) suur sisaldus veres viitab vähi olemasolu võimalusele.
English: Axumin can only be obtained with a prescription.
Estonian: Axumin on retseptiravim.
English: How is Axumin used?
Estonian: Kuidas Axumini kasutatakse?
English: What benefits of Axumin have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Axumini kasulikkus?
English: The PET images must be read by nuclear medicine physicians trained in interpreting PET scan images with Axumin.
Estonian: Tulemusi peab tõlgendama PET-uuringute kujutiste tõlgendamise väljaõppega tervishoiutöötaja.
English: Furthermore, the risk from radiation is very low.
Estonian: Peale selle on kiirituse tekitatav risk väga väike ning arstidel soovitatakse kasutada väikseimaid vajalikke annuseid.
English: Depending on the person reading the scans, only 17 to 54% of patients whose tissue samples did not show cancer had a negative scan result.
Estonian: Meestel, kellel PET-uuringute järgi ei olnud vähk taastekkinud, olid uuringutulemused õiged 92% juhtudest.
English: Pharmaceutical form Route of administration
Estonian: Ravimvorm Manustamistee Sisepakendi iseloomustus
English: MA (EU) number (Invented) name
Estonian: (Väljamõeld ud) nimetus
English: 1 pre-filled syringe with needle safety guard
Estonian: Nõelakaitsega 0,7 ml (10000 RÜ/ml) 1 süstel
English: Pack size
Estonian: 1 süstel
English: Outcome of a procedure under Article 31 of Directive 2001/83/EC as amended
Estonian: Muudetud direktiivi 2001/83/EÜ artikli 31 kohase esildismenetluse tulemused
English: • Patients with any question should speak to their doctor or pharmacist.
Estonian: • Küsimuste korral peab patsient pöörduma arsti või apteekri poole.
English: The European Commission issued a decision for aprotinin on 18 September 2013.
Estonian: Euroopa Komisjon tegi otsuse aprotiniini kohta 18. septembril 2013.
English: What are antifibrinolytics?
Estonian: Mis on antifibrinolüütilised ravimid?
English: New analyses showed flaws in the way the study was carried out, which cast doubt on the previous conclusions.
Estonian: Uued analüüsid näitasid, et uuringu ülesehituses oli puudusi, mis seab varasemad järeldused kahtluse alla.
English: What are the recommendations for patients and prescribers?
Estonian: Mis on komitee soovitused patsientidele ja ravimit määravatele arstidele?
English: They have been used for several decades in patients undergoing certain dental or surgical operations as well as other patients at risk of complications from bleeding.
Estonian: Neid on kasutatud aastakümneid patsientidel, kellele tehakse teatud invasiivseid hambaraviprotseduure või kirurgilisi operatsioone, ning muudel patsientidel, kellel on verejooksudest tulenevate tüsistuste risk.
English: The Committee also looked at data from other clinical studies, the published literature, spontaneous reports of side effects and data submitted by companies that market antifibrinolytics.
Estonian: Komitee vaatas läbi ka teiste kliiniliste uuringute, avaldatud kirjanduse, kõrvalnähtude spontaansete teadete andmeid ning antifibrinolüütikume turustavate ettevõtete esitatud andmed.
English: Why were antifibrinolytics reviewed?
Estonian: Miks antifibrinolüütiliste ravimite teave läbivaadati?
English: On 5 November 2007, the German medicines regulatory authority (BfArM) suspended the marketing authorisations for aprotinin-containing medicines in Germany.
Estonian: 5. novembril 2007 peatas Saksamaa Ravimiamet (BfArM) Saksamaal aprotiniini sisaldavate ravimite müügiloa.
English: The Committee has agreed with the companies marketing these medicines on a letter to be sent out to relevant healthcare professionals in the EU explaining the changes to the prescribing information.
Estonian: Komitee leppis ravimeid turustavate ettevõtetega kokku, et Euroopa Liidu asjaomastele tervishoiutöötajatele saadetakse teatis, milles selgitatakse ravimi määramise teabe muudatusi.
English: Aprotinin had been approved in several EU countries for patients undergoing heart bypass surgery but was suspended in the EU by the European Commission in February 2008.
Estonian: Aprotiniin oli mitmes Euroopa Liidu liikmesriigis näidustatud kasutamiseks patsientidel, kellele tehakse südame pärgarteri šuntimisoperatsioon, kuid Euroopa Komisjon peatas 2008. aasta veebruaris müügiloa Euroopa Liidus.
English: The CHMP was informed of ongoing pharmacokinetic studies which are to be finalised and assessed by national authorities.
Estonian: Inimravimite komiteele esitati praegu toimuvate farmakokineetikauuringute andmed, mille lõpetavad ja mida hindavad riikide ametiasutused.
English: There were also problems with the way data from some patients were excluded from the initial analyses and with the lack of appropriate monitoring of blood-thinning medicines the patients were taking.
Estonian: Probleeme esines ka meetodites, kuidas osade patsientide andmed jäeti esialgsetest analüüsidest kõrvale, ja sellega, et patsientidele manustatavate antikoagulantide asjakohane jälgimine puudus.
English: Aminocaproic acid and tranexamic acid are the commonly used antifibrinolytics in the EU.
Estonian: Aminokaproonhape ja traneksaamhape on Euroopa Liidus tavalised antifibrinolüütikumid.
English: • When aprotinin becomes available again, prescribers are advised to note the revised indication and to adhere closely to the updated prescribing advice.
Estonian: • Kui aprotiniini turustamine algab uuesti, peavad ravimit määravad arstid arvestama läbivaadatud näidustust ning järgima hoolikalt uusi ravimi määramise soovitusi.
English: As these medicines have been authorised since the 1960s, the CHMP reviewed the available evidence on their benefits in various conditions and made recommendations to harmonise the conditions for which these medicines should be used in the EU.
Estonian: Nendel ravimitel on müügiluba juba alates 1960. aastatest, mistõttu vaatas inimravimite komitee üle olemasolevad andmed nende kasulikkuse kohta mitmesugustes tingimustes ning soovitas, kuidas saab nende ravimite kasutustingimusi Euroopa Liidus ühtlustada.
English: Prescribers will be sent information on how to use the registry.
Estonian: Ravimit määravatele arstidele saadetakse teave, kuidas patsiendiregistrit kasutada.
English: The CHMP also recommended important changes to the prescribing information for aprotinin medicines, including restricting their use to isolated heart bypass surgery in adults at high risk of major blood loss and the inclusion of a warning on the risk of giving patients too little heparin (‘under heparinisation').
Estonian: Inimravimite komitee soovitas teha ka olulisi muudatusi aprotiniini sisaldavate ravimite määramise teabes, sealhulgas piirates nende kasutamist südame pärgarteri isoleeritud šuntimisoperatsiooni korral suure verekaotuse riskiga täiskasvanutega ning lisades hoiatuse patsientidele liiga väikeses koguses hepariini manustamise kohta (nn alahepariniseerimine).
English: On 19 June 2012, following a re-examination, the CHMP confirmed its initial conclusions but decided to remove a requirement for a pharmacokinetic study with tranexamic acid.
Estonian: 19. juunil 2012 kinnitas inimravimite komitee pärast taasläbivaatamist oma varasemaid järeldusi, kuid otsustas loobuda traneksaamhappe farmakokineetikauuringu nõudest.
English: The European Commission issued a decision for aminocaproic acid on 10 October 2012.
Estonian: Euroopa Komisjon tegi otsuse aminokaproonhappe kohta 10. oktoobril 2012.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of these medicines outweigh their risks and recommended that the EU-wide suspension of the marketing authorisation for aprotinin-containing medicines that has been in place since 2008 be lifted.
Estonian: EMA inimravimite komitee järeldas, et nende ravimite kasulikkus on suurem kui nendega kaasnevad riskid, ja soovitas, et aprotiniini sisaldavate ravimite müügiloa peatamine, mis on kehtinud kogu Euroopa Liidus alates 2008. aastast, tuleb lõpetada.
English: The way additional blood-thinning treatments (such as heparin) were used in the study was inconsistent and sometimes inappropriate, and this could have contributed to higher than expected rates of deaths in patients on aprotinin.
Estonian: Täiendavate antikoagulantide (hüübimisvastaste ainete, nt hepariini) kasutamine uuringus oli ebaühtlane ja mõnikord asjakohatu, mis võis aidata kaasa aprotiniini kasutanud patsientide eeldatust suuremale suremusele.
English: This decision was triggered by the early results of a study (the BART study) that showed a higher number of deaths 30 days after heart surgery among patients given aprotinin compared with patients given other antifibrinolytic treatments (aminocaproic acid and tranexamic acid).
Estonian: Selle otsuse tingisid ühe uuringu (BART-uuringu) esialgsed tulemused, mille kohaselt oli aprotiniini kasutanud patsientide suremus 30 päeva pärast südameoperatsiooni suurem kui teistel antifibrinolüütikume (aminokaproonhapet ja traneksaamhapet) kasutanud patsientidel.
English: In patients at risk of significant bleeding, antifibrinolytics ensure that blood clots are not broken down too rapidly, which helps to reduce blood loss.
Estonian: Suure verejooksuriskiga patsientidel tagatakse antifibrinolüütikumide kasutamisega, et verehüübed lagunevad aeglasemalt, mis aitab vähendada verekaotust.
English: The CHMP set out conditions for the reintroduction of aprotinin medicines onto the market and also made recommendations on the use of aminocaproic acid and tranexamic acid.
Estonian: Inimravimite komitee kehtestas aprotiniini sisaldavate ravimite turule tagasitoomise tingimused ning andis ka aminokaproonhappe ja traneksaamhappe kasutamise soovitusi.
English: On 12 March 2010, the German medicines agency asked the CHMP to carry out a full assessment of the benefits and risks of aprotinin, as well as those of aminocaproic acid and tranexamic acid, and to issue an opinion on their authorisation in the EU.
Estonian: 12. märtsil 2010 palus Saksamaa Ravimiamet inimravimite komiteel aprotiniini, aminokaproonhappe ja traneksaamhappe kasulikkust ja riske põhjalikult hinnata ning esitada arvamus nende ravimite müügiloa kohta Euroopa Liidus.
English: Furthermore, the CHMP advised that careful consideration be given to benefits and risks of aprotinin, and the availability of alternative treatments.
Estonian: Samuti soovitas inimravimite komitee hoolikalt kaaluda aprotiniini kasulikkust ja riske ning teisi raviviise.
English: The current CHMP review was initiated at the request of the German medicines agency to take into account further data and analyses from the BART study and other sources that have become available since 2007.
Estonian: Käesolev inimravimite komitee korraldatav andmete läbivaatamine algatati Saksamaa Ravimiameti taotlusel, kes palus arvestada BART-uuringu uusi andmeid ja analüüse ning muid alates 2007. aastast kättesaadavad olnud allikaid.
English: • Prescribers should follow the new harmonised recommendations for the use of aminocaproic acid and tranexamic acid.
Estonian: • Ravimit määravad arstid peavad järgima aminokaproonhappe ja traneksaamhappe uusi ühtlustatud kasutussoovitusi.
English: A registry will be set up in the EU to monitor the use of aprotinin, and the CHMP has approved a risk management plan for aprotinin medicines.
Estonian: Euroopa Liidus luuakse aprotiniini kasutamise jälgimiseks patsiendiregister ning inimravimite komitee on heaks kiitnud aprotiniini sisaldavate ravimite riskijuhtimiskava.
English: The CHMP's review of aminocaproic acid and tranexamic acid, which are currently on the market in the EU, did not reveal any new safety concerns.
Estonian: Inimravimite komitee vaatas läbi ka praegu Euroopa Liidus turustatavate aminokaproonhappe ja traneksaamhappe teabe, kuid selles ei ilmnenud uusi ohutusprobleeme.
English: The CHMP revisited its previous recommendation on aprotinin, taking into account the new information from the BART study.
Estonian: Inimravimite komitee vaatas läbi oma varasema soovituse aprotiniini kohta, arvestades BART-uuringu uusi andmeid.
English: The results from the BART study were not replicated in other studies, and when data from several studies (excluding BART) were analysed together, the results did not show that aprotinin is linked to a higher risk of death compared with other antifibrinolytics.
Estonian: Teised uuringud ei korranud BART-uuringu tulemusi ning mitme muu kui BART-uuringu andmete koondanalüüsi tulemused ei näidanud aprotiniini seost suurema suremusega kui teiste antifibrinolüütikumide kasutamisel.
English: The European Commission issued a decision for tranexamic acid on 10 October 2012.
Estonian: Euroopa Komisjon tegi otsuse traneksaamhappe kohta 10. oktoobril 2012.
English: On 14 February 2012, the European Medicines Agency completed a review of the antifibrinolytic medicines aprotinin, aminocaproic acid and tranexamic acid.
Estonian: 14. veebruaril 2012 lõpetas Euroopa Ravimiamet (EMA) antifibrinolüütiliste ravimite aprotiniini, aminokaproonhappe ja traneksaamhappe andmete läbivaatamise.
English: Antifibrinolytics are medicines used to prevent excessive blood loss.
Estonian: Antifibrinolüütilised ravimid ehk antifibrinolüütikumid on ravimid, millega ennetatakse liigset verekaotust.
English: The CHMP reviewed data from the BART study, including additional data and analyses that became available since 2007.
Estonian: Inimravimite komitee vaatas läbi BART-uuringu andmed, sealhulgas alates 2007. aastast kättesaadavad olnud täiendavad andmed ja analüüsid.
English: The amended prescribing information on aprotinin medicines for doctors can be found here.
Estonian: Muudetud määramisteave arstidele aprotiniini sisaldavate ravimite kohta on siin.
English: The CHMP therefore concluded that the benefits of aprotinin outweigh its risk in appropriately managed patients undergoing isolated heart bypass surgery (not combined with other heart surgery), and recommended that the suspension of aprotinin medicines in the EU be lifted for this revised indication.
Estonian: Inimravimite komitee järeldas seepärast, et aprotiniini kasulikkus patsientidel, kellele tehakse südame pärgarteri isoleeritud (muu südameoperatsiooniga mitteseostuv) šuntimisoperatsioon, on õige kasutamise korral suurem kui riskid, ning soovitas aprotiniini sisaldavate ravimite müügiloa peatamise Euroopa Liidus selle läbivaadatud näidustuse korral lõpetada.
English: The amended information for tranexamic acid can be found here.
Estonian: Traneksaamhappe muudetud teave on siin.
English: The amended prescribing information on aminocaproic acid for doctors can be found here.
Estonian: Muudetud määramisteave arstidele aminokaproonhappe kohta on siin.
English: • A registry will be set up in EU monitor the pattern of use of aprotinin.
Estonian: • Aprotiniini kasutusviiside jälgimiseks luuakse Euroopa Liidu patsiendiregister.
English: Questions and answers on the suspension of aprotinin
Estonian: 1 Aprotiniini müügiloa peatamise teave
English: Antifibrinolytics work by preventing fibrinolysis, the natural process by which blood clots are broken down.
Estonian: Antifibrinolüütikumid takistavad fibrinolüüsi ehk verehüüvete looduslikku lagunemist.
English: During the review, the CHMP took advice from a scientific advisory group, consisting of experts in cardiovascular and bleeding disorders.
Estonian: Läbivaatamisel arvestas inimravimite komitee kardiovaskulaarsete haiguste ja hüübimishäirete teadusnõuanderühma arvamust.
English: The suspension in Germany led to an EU-wide review by the CHMP which recommended the suspension of aprotinin throughout the EU on 21 November 2007.
Estonian: Ravimi müügiloa peatamise tõttu Saksamaal vaatas inimravimite komitee ravimi andmed kogu Euroopa Liidus üle ning soovitas 21. novembril 2007 aprotiniini kasutamise kogu Euroopa Liidus peatada.1 Soovituse andmise ajal kavatses inimravimite komitee BART-uuringu lõplike tulemuste selgumise järel ravimi andmed uuesti läbi vaadata.
English: They work by reducing the activity of an enzyme called plasmin that is responsible for breaking up the fibres in blood clots.
Estonian: Sellise toime tekitab antifibrinolüütikumide omadus vähendada ensüümi plasmiini aktiivsust; plasmiin lagundab verehüüvete kiude.
English: HU - Hungary sanofi-aventis Zrt.
Estonian: HU - Ungari sanofi-aventis Zrt.
English: List of the invented names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the member states
Estonian: Ravimite nimetuste, ravimvormide, tugevuste, manustamisviiside, müügiloa hoidjate loetelu liikmesriikides
English: TRANEXAMICO BIOINDUTRIA L.I.M.
Estonian: Acido tranexamico bioindutria L.I.M
English: CY - Cyprus
Estonian: CY - Küpros
English: NO - Norway
Estonian: NO - Norra
English: Tranexamic acid containing medicinal products with Marketing Authorisation in the European Union
Estonian: Euroopa Liidus kehtivate müügilubadega traneksaamhapet sisaldavad ravimid
English: Rivium Westlaan 142 2909 LD, Capelle a/d Ijssel
Estonian: Pfizer B.V., Rivium Westlaan 142, 2909 LD, Capelle a/d Ijssel
English: Pharmacia GmbH Linkstr.
Estonian: DE - Saksamaa Pharmacia GmbH Linkstr.
English: Annex I
Estonian: Lisa I
English: CZ - Czech Republic Sanofi-Aventis, s.r.o., Evropská 846/176a, 160 00
Estonian: Sanofi-Aventis, s.r.o., Evropská 846/176a, 160 00 Praha 6, Czech Republic
English: Sanofi Aventis France 1-13, bd Romain Rolland 75014 Paris
Estonian: FR - Prantsusmaa Sanofi Aventis France 1-13, bd Romain Rolland 75014 Paris
English: LU - Luxembourg PFIZER S.A.N.V.
Estonian: LU - Luksemburg Pfizer S.A.N.V.
English: NL - Netherlands
Estonian: NL - Holland
English: PL - Poland
Estonian: PL - Poola
English: 191 90 Sollentuna Sweden
Estonian: Pfizer AB , 191 90 Sollentuna, Sweden
English: SE - Sweden
Estonian: SE - Rootsi
English: EL - Greece
Estonian: EL - Kreeka
English: UK - United Kingdom Pharmacia Limited Walton Oaks, Dorking Road, Tadworth
Estonian: Pharmacia Limited, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS United Kingdom
English: ET - Estonia
Estonian: ET - Eesti
English: IT - Italy
Estonian: IT - Itaalia
English: ES - Spain
Estonian: ES - Hispaania
English: IE - Ireland
Estonian: IE - Iirimaa
English: DK - Denmark
Estonian: DK - Taani
English: FI - Finland
Estonian: FI - Soome
English: INJECTION
Estonian: Süst
English: IS - Iceland
Estonian: IS - Island
English: Sanofi-Aventis France Boulevard Romain Rolland 113, F-75014 Paris, France solution for infusion intravenous use
Estonian: Sanofi-Aventis France boulevard Romain Rolland 1-13, F-75014 Paris, France
English: LU - Luxembourg Eumedica SA 67, Avenue Winston Churchill B- 1180 Bruxelles
Estonian: LU - Luksemburg Eumedica SA 67, Avenue Winston Churchill
English: 1180 Brussels
Estonian: B- 1180 Bruxelles
English: 01-207 Warsaw, Poland solution for infusion intravenous use
Estonian: 01-207 Warsaw, Poland
English: 1324 Lysaker Norway
Estonian: Pfizer AS, Postboks 3, 1324 Lysaker Norway
English: intravenous use
Estonian: Infusioonilahus Intravenoosne
English: Pfizer B.V.
Estonian: Pfizer S.A.N.V.
English: Praha 6, Czech Republic
Estonian: CZ - Tšehhi Vabariik
English: Solution for Injection or infusion intravenous use
Estonian: Süste- või infusioonilahus
English: The two studies together involved a total of 614 patients.
Estonian: Kahes uuringus osales kokku 614 patsienti.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Invega on 25 June 2007.
Estonian: Euroopa Komisjon andis Invega müügiloa, mis kehtib kogu Euroopa Liidus, 25. juunil 2007.
English: What measures are being taken to ensure the safe and effective use of Invega?
Estonian: Mis meetmed võetakse, et tagada Invega ohutu ja efektiivne kasutamine?
English: What is Invega and what is it used for?
Estonian: Mis on Invega ja milleks seda kasutatakse?
English: This summary was last updated in 09-2017.
Estonian: Kokkuvõtte viimane uuendus: 09-2017.
English: Schizophrenia
Estonian: Skisofreenia
English: The full EPAR for Invega can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Invega kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Invega paliperidone
Estonian: Invega paliperidoon
English: The European Medicines Agency decided that Invega's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Euroopa Ravimiamet otsustas, et Invega kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: What are the risks associated with Invega?
Estonian: Mis riskid Invegaga kaasnevad?
English: It is available as prolonged-release tablets (3, 6, 9 and 12 mg).
Estonian: Ravimit turustatakse toimeainet pikaajaliselt vabastavate tablettidena (3, 6, 9 ja 12 mg).
English: ‘Prolonged release' means that paliperidone is released slowly from the tablet over a few hours.
Estonian: Toimeaine pikaajaline vabastamine tähendab, et paliperidoon vabaneb tabletist aeglaselt mõne tunni jooksul.
English: Patients can take Invega either with food or between meals, but should not switch between taking it with food on one day and between meals on another.
Estonian: Invegat võib manustada kas koos toiduga või toidukordade vahepeal, kuid patsiendid ei tohi manustada ravimit vaheldumisi ühel päeval toiduga ja teisel päeval toidukordade vahepeal.
English: Why is Invega approved?
Estonian: Miks Invega heaks kiideti?
English: Similar results were seen in the other two short-term studies, with higher doses of Invega being more effective than lower doses.
Estonian: Sarnaseid tulemusi täheldati teises kahes lühiajalises uuringus, kusjuures Invega suuremad annused olid efektiivsemad kui väiksemad annused.
English: Side effects in adolescents are similar to those in adults, although some side effects may occur more frequently.
Estonian: Noorukite kõrvalnähud on täiskasvanute omadega sarnased, ehkki teatud kõrvalnähte esineb sagedamini.
English: How is Invega used?
Estonian: Kuidas Invegat kasutatakse?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Invega have been included in the summary of product characteristics and the package leaflet.
Estonian: Invega ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: It is not intended to provide practical advice on how to use Invega.
Estonian: Hindamisaruandes ei anta Invega kasutamise praktilisi nõuandeid.
English: Studies in adolescents have shown similar results with Invega to those seen in adults.
Estonian: Noorukitel tehtud uuringutes on Invega tulemused sarnased täiskasvanute tulemustega.
English: Other information about Invega
Estonian: Muu teave Invega kohta